ALKS Alkermes plc.
Price Chart
Executive Summary
Two Alkermes insiders — the Chief Medical Officer and the Interim Principal Accounting Officer — sold a combined $1.06M in open-market sales over a 4-day window, with the CMO also exercising stock options. The total sales represent ~0.015% of the $7.0B market cap, well below the 0.1% materiality threshold, and the CMO's sale is paired with a same-day option exercise, suggesting a tax- or liquidity-driven transaction rather than a bearish signal. No material corporate event (earnings, guidance, M&A) accompanies these routine sales.
Key Financial Metrics
Actionable Insight
These sales are routine and non-informative — both insiders sold in conjunction with option exercises, a pattern consistent with tax withholding or diversification. The dollar amount is negligible relative to market cap. No action warranted; monitor for any change in pattern (e.g., C-suite open-market selling without option exercise) or a material corporate event that could alter the read.
Key Facts
- Total insider sales of $1.06M represent ~0.015% of Alkermes' $7.0B market cap — trivial by proportionality standards.
- CMO Hopkinson sold 9,000 shares ($375K) on June 1, simultaneously exercising 10,000 derivative shares (5,000 at $0, 5,000 at $19.34) — a classic cashless exercise pattern.
- Interim PAO Parisi sold 16,217 shares ($687K) on May 29, paired with exercise of 6,784 derivative shares — also consistent with a cashless exercise.
- No open-market purchases were made by any insider in the cluster window.
- Prior 30-day insider activity was limited to $1.1M in sales — no unusual acceleration or change in pattern.
Financial Impact
Total insider sales of $1.06M, or ~0.015% of market cap — immaterial.
Risk Factors
- If a material adverse event (e.g., clinical trial failure, FDA setback) emerges in the coming weeks, these sales could be viewed as opportunistic in hindsight.
- The CMO's sale is the first disclosed trade in the filing window — a larger cluster of C-suite open-market sales without option exercises would be more concerning.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ALKS-1780356434266 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
Insider Cluster
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
4d ago
|
Insider Cluster
| — | awaiting T+5 | — | — |
|
May 20, 2026
16d ago
|
8-K
| — | awaiting T+5 | — | — |
|
May 13, 2026
23d ago
|
DEFA14A
| — | awaiting T+5 | — | — |
|
May 12, 2026
24d ago
|
8-K
| $38.26 $37.19 | ▼ −2.79% | ▼ −2.87% | $42.80 (+11.87%) |
|
May 5, 2026
4w ago
|
8-K
| $36.23 $38.26 | ▲ +5.60% | ▲ +3.62% | $42.80 (+18.14%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $33.26 $35.40 | ▲ +6.44% | ▲ +4.10% | $42.80 (+28.69%) |
|
Mar 2, 2026
13w ago
|
Insider Cluster
| $30.24 $28.45 | ▼ −5.92% | ▼ −4.71% | $42.80 (+41.55%) |
|
Feb 25, 2026
14w ago
|
8-K
| $31.03 $29.16 | ▼ −6.03% | ▼ −4.93% | $42.80 (+37.94%) |
|
Feb 25, 2026
14w ago
|
8-K
| $31.03 $29.16 | ▼ −6.03% | ▼ −4.93% | $42.80 (+37.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access